Growth and Growth Hormone Use in Osteogenesis Imperfecta - Osteogenesis Imperfecta - page 253

childhood short stature: preliminary report of the French SAGhE
study. J Clin Endocrinol Metab 2012;97(2):416-25.

[148] Wright NM. Just taller or more bone? The impact of growth
hormone on osteogenesis imperfecta and idiopathic juve-
nile osteoporosis. J Pediatr Endocrinol Metab 2000;13(Suppl.
2):999-1002.
[149] Vieira NE, Marini JC, Hopkins E, Abrams SA, Yergey AL. Effect
of growth hormone treatment on calcium kinetics in patients with
osteogenesis imperfecta type III and IV. Bone 1999;25(4):501-5.
[150] King D, Chase J, Havey RM, Voronov L, Sartori M, McEwen
HA, et al. Effects of growth hormone transgene expression on
vertebrae in a mouse model of osteogenesis imperfecta. Spine
(Phila Pa 1976) 2005;30(13):1491-5.
[151] King D, Jarjoura D, McEwen HA, Askew MJ. Growth hormone
injections improve bone quality in a mouse model of osteogen-
esis imperfecta. J Bone Miner Res 2005;20(6):987-93.
[152] ClinicalTrials.gov. Growth Hormone Therapy in Osteogenesis
Imperfecta, < http://clinicaltrials.gov/ct2/show/NCT00001305 >.
Cited; available from: < http://clinicaltrials.gov/ct2/show/
NCT00001305 >.

[137] Savendahl L, Maes M, Albertsson-Wikland K, Borgstrom B, Carel

JC, Henrard S, et al. Long-term mortality and causes of death in
isolated GHD, ISS, and SGA patients treated with recombinant
growth hormone during childhood in Belgium, The Netherlands,
and Sweden: preliminary report of 3 countries participating in
the EU SAGhE study. J Clin Endocrinol Metab 2012;97(2):E213-7.

[138] Plotkin H, Rauch F, Bishop NJ, Montpetit K, Ruck-Gibis J,

Travers R, et al. Pamidronate treatment of severe osteogenesis
imperfecta in children under 3 years of age. J Clin Endocrinol
Metab 2000;85(5):1846-50.

[139] Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers

R. Cyclic administration of pamidronate in children with severe
osteogenesis imperfecta. N Engl J Med 1998;339:947-52.

[140] Halasy-Nagy JM, Rodan GA, Reszka AA. Inhibition of bone

resorption by alendronate and risedronate does not require
osteoclast apoptosis. Bone 2001;29(6):553-9.

[141] Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman

GD, et al. Bisphosphonates promote apoptosis in murine osteo-
clasts in vitro and in vivo. J Bone Miner Res 1995;10(10):1478-87.

[153] Antoniazzi F, Monti E, Venturi G, Franceschi R, Doro F, Gatti

D, et al. GH in combination with bisphosphonate treatment in
osteogenesis imperfecta. Eur J Endocrinol 2010;163(3):479-87.

[142] Pataki A, Muller K, Green JR, Ma YF, Li QN, Jee WS. Effects

of short-term treatment with the bisphosphonates zoledronate
and pamidronate on rat bone: a comparative histomorphomet-
ric study on the cancellous bone formed before, during, and
after treatment. Anat Rec 1997;249(4):458-68.

[154] Kodama H, Kubota K, Abe T. Osteogenesis imperfecta: are

fractures and growth hormone treatment linked?. J Pediatr
1998;132(3 Pt 1):559-60.

[155] Montpetit K, Plotkin H, Rauch F, Bilodeau N, Cloutier S,

Rabzel M, et al. Rapid increase in grip force after start of pami-
dronate therapy in children and adolescents with severe osteo-
genesis imperfecta. Pediatrics 2003;111(5 Pt 1):e601-3.

[143] Evans KD, Lau ST, Oberbauer AM, Martin RB. Alendronate

affects long bone length and growth plate morphology in
the oim mouse model for Osteogenesis Imperfecta. Bone
2003;32(3):268-74.

[156] Takken T, Terlingen HC, Helders PJ, Pruijs H, Van der Ent CK,

Engelbert RH. Cardiopulmonary itness and muscle strength
in patients with osteogenesis imperfecta type I. J Pediatr
2004;145(6):813-8.

[144] Arikoski P, Silverwood B, Tillmann V, Bishop NJ. Intravenous

pamidronate treatment in children with moderate to severe
osteogenesis imperfecta: assessment of indices of dual-energy
X-ray absorptiometry and bone metabolic markers during the
irst year of therapy. Bone 2004;34(3):539-46.

[157] Frost HM, Schonau E. The “muscle-bone unit” in children

and adolescents: a 2000 overview. J Pediatr Endocrinol Metab
2000;13(6):571-90.

[145] Munns CF, Cowell CT. Prevention and treatment of osteo-

porosis in chronically ill children. J Musculoskelet Neuronal
Interact 2005;5(3):262-72.

[158] Astrom E, Soderhall S. Beneicial effect of long term intrave-

nous bisphosphonate treatment of osteogenesis imperfecta.
Arch Dis Child 2002;86(5):356-64.

[146] Kruse HP, Kuhlencordt F. On an attempt to treat primary and

secondary osteoporosis with human growth hormone. Horm
Metab Res 1975;7(6):488-91.

[159] Land C, Rauch F, Montpetit K, Ruck-Gibis J, Glorieux FH.

Effect of intravenous pamidronate therapy on functional abili-
ties and level of ambulation in children with osteogenesis
imperfecta. J Pediatr 2006;148(4):456-60. [147] Rauch F, Travers R, Paritt AM, Glorieux FH. Static and

dynamic bone histomorphometry in children with osteogen-
esis imperfecta. Bone 2000;26(6):581-9.